Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesXvivo Perfusion AB

Xvivo Perfusion AB

PortfolioPortfolio WatchlistWatchlist
Company price
202.2 GBX 0.20 ( 0.10%)
Last update at 2026-10-27T16:10:00Z
VOLUME
11924
Market Cap
6660.19M
P/E
10.61

Momentum Score

…

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
199.20
Low
202.40
High
52 Week Price Range
160.80
Low
333.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
202.00
Dividend Yield
-
Revenue TTM
812.16M
Revenue Per Share
25.78
Gross Profit TTM
599.49M
Debt / Equity
0.11
ROE
1.18%
Net Debt
-54.20M
ROCE
3.68%
Diluted EPS TTM
0.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 38.56M 199.95M 94.52M 22.31M 6.67M
Net income 25.16M 172.18M 91.82M 18.43M 8.15M
Selling general administrative 78.14M 95.79M 76.94M 62.58M 55.69M
Selling and marketing expenses 298.94M 283.98M 232.26M 152.40M 97.69M
Gross profit 533.50M 616.41M 445.11M 296.96M 188.28M
Ebit 82.93M 205.55M 4.19M 12.85M -18.74M
Ebitda 153.14M 272.97M 35.05M 21.70M -11.70M
Depreciation and amortization 70.21M 67.42M 30.86M 8.85M 7.04M
Operating income 93.02M 88.35M 4.19M 12.85M -18.74M
Other operating expenses 719.15M 734.06M 593.36M 394.50M 251.44M
Interest expense 44.37M 5.60M 1.19M - 0.00M
Tax provision - - - - -1.49M
Interest income - - - - 25.16M
Income tax expense 13.40M 27.77M 2.70M 3.89M 1.49M
Total revenue 812.16M 822.41M 597.54M 415.29M 258.39M
Total operating expenses 440.48M 528.06M 440.92M 276.16M 181.34M
Cost of revenue 278.67M 206.00M 152.43M 118.34M 70.11M
Total other income expense net -54.46M 111.59M 90.33M 9.46M 25.41M
Net income applicable to common shares - - - 18.43M 8.15M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2374.11M 2402.74M 2195.61M 1733.08M 1542.60M
Intangible assets 840.29M 724.80M 628.97M 8.48M 8.66M
Other current assets - 38.03M 40.59M 19.90M 19.21M
Total liab 260.65M 245.97M 250.57M 302.95M 257.15M
Total stockholder equity 2113.46M 2156.78M 1945.05M 1430.14M 1285.45M
Deferred long term liab - - - 544.51M 456.55M
Other current liab - 115.21M 72.60M 96.43M 83.07M
Common stock 0.82M 0.81M 0.81M 0.76M 0.75M
Retained earnings 316.90M 291.75M 119.57M 27.75M 9.28M
Other liab - - - 163.60M 151.10M
Good will 610.06M 682.48M 591.39M 625.32M 460.23M
Other assets - - - 583.78M 498.72M
Cash 292.09M 415.52M 545.79M 246.54M 398.70M
Total current liabilities 119.38M 177.51M 134.49M 134.90M 104.52M
Current deferred revenue - - 3.69M - -
Net debt -54.20M -381.48M -514.35M -246.54M -398.70M
Short term debt 11.56M 10.92M 10.27M - -
Short long term debt total 237.89M 34.04M 31.44M - 1.52M
Other stockholder equity 1785.08M 1772.03M 1763.78M 1401.62M 1275.42M
Property plant equipment - - - 47.58M 26.30M
Total current assets 688.21M 813.08M 826.40M 467.51M 547.53M
Net tangible assets - - - 796.33M 816.56M
Short term investments - - 300.00M - -
Net receivables 147.66M 132.12M 98.13M 94.50M 52.04M
Long term debt - - - - 1.52M
Inventory 248.46M 227.41M 141.60M 106.57M 77.59M
Accounts payable 107.82M 39.45M 36.05M 38.47M 21.45M
Accumulated other comprehensive income 10.65M 92.19M 60.88M - -
Non currrent assets other - 0.90M 598.50M -681.79M -496.34M
Non current assets total 1685.90M 1589.67M 1369.21M 681.79M 496.34M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -0.40M
Change to liabilities - - - 11.02M 0.00M
Total cashflows from investing activities -258.41M -243.81M -161.62M -197.62M -187.70M
Net borrowings - - - - -10.74M
Total cash from financing activities 72.25M -10.90M 418.55M -6.84M 234.61M
Change to operating activities - - - - -1.12M
Net income 25.16M 199.95M 91.82M 18.43M 8.15M
Change in cash -123.43M -130.57M 299.54M -152.15M 44.46M
Begin period cash flow 415.52M 546.09M 246.54M 398.70M 354.24M
End period cash flow 292.09M 415.52M 546.09M 246.54M 398.70M
Total cash from operating activities 101.07M 111.29M 46.29M 27.86M -12.06M
Depreciation 70.21M - 30.86M 15.23M 11.88M
Other cashflows from investing activities -258.41M -193.46M -100.92M 0.78M -0.40M
Change to inventory -37.94M -77.52M -33.48M -6.33M -13.80M
Change to account receivables 8.79M -17.77M -25.03M -26.86M -8.29M
Other cashflows from financing activities 72.25M -10.90M -10.70M 0.45M 245.35M
Change to netincome - - - -10.57M -29.25M
Capital expenditures 101.07M 193.15M 43.02M 18.18M 10.19M
Change in working capital -68.73M -79.11M -39.22M -33.19M -22.10M
Stock based compensation - - 2.30M 6.69M 2.60M
Other non cash items 74.42M -9.54M -39.47M 20.70M -12.60M
Free cash flow - -81.86M -97.65M 9.67M -22.25M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0RKL
Xvivo Perfusion AB		 0.20
0.10%		 202.20 10.61 - 8.20 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Gemenskapens gata 9, Mölndal, Sweden, 431 53

46 3 17 88 21 50

https://www.xvivogroup.com

198

Name Title Year Born
Mr. Christoffer Rosenblad Chief Exec. Officer 1975
Mr. Kristoffer Nordstrom CFO & Investor Relations 1985
Ms. Lena Hagman B.Sc. Chief Operating Officer 1965
Dr. Magnus Nilsson Ph.D. Sr. Advisor 1956
Ms. Katrin Gisselfalt Ph.D. Global Quality Assurance & Regulatory Affairs Director 1969
Mr. Andreas Wallinder M.D., Ph.D. Chief Medical Officer 1977
Mr. Johan Holmstrom Chief Commercial Officer 1970
Ms. Charlotte Walldal Global R&D director 1967
Jaya Tiwari VP Clinical and Regulatory Affairs NA
Mr. Christer de Flon Mang. 1949

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…